Tectonic Therapeutic to Participate in March Investor Conferences
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.
The company will provide live webcasts of both events, accessible through the 'Events & Presentations' section of their website at www.tectonictx.com. Recordings will remain available for approximately 90 days after the conferences conclude.
The management team will conduct one-on-one meetings with investors during both conferences. Interested parties are advised to contact their TD Cowen and/or Leerink representatives to arrange meetings.
Details
News Market Reaction – TECX
The recorded move for TECX in the trading session of this news was -2.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.
| TD Cowen 45th Annual Health Care Conference | |
| Date: | March 5, 2025 |
| Time: | 9:50 AM EST |
| Location: | Boston, MA |
| Format: | Corporate Presentation |
| Presenter: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
| Leerink Partners Global Healthcare Conference | |
| Date: | March 11, 2025 |
| Time: | 11:20 AM EDT |
| Location: | Miami, FL |
| Format: | Fireside Chat |
| Presenters: | Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer |
| Webcast: | Link |
Both live webcasts can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.
The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.
About Tectonic
Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.